Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Tonix In The News

Home
Investors
News / Press Releases
Tonix In The News

Tonix In The News

Tonix receives IND approval for sublingual formulation to treat PTSD

Fierce Drug Delivery |

June 10, 2014

Tonix's sublingual formulation for fibromyalgia reaches pivotal trial stage

Fierce Drug Delivery |

May 13, 2014

Fibromyalgia Drugs: Successes or Failures?

National Pain Report |

April 23, 2014

Seth Lederman's Tonix Pharmaceuticals taking shorter path to drug approval

New York Business Journal |

April 4, 2014

Seth Lederman: Turning something old into something new (Part 2 of 2)

DDN News |

March 14, 2014

Tonix CEO: Investors Seeing Value in Reformulation Strategy

TheStreet |

February 14, 2014

Seth Lederman: Looking to past medications for the future (Part 1 of 2)

DDN News |

February 13, 2014

The Road More Traveled: Improving Drug Therapies for Not-So-Rare Diseases

Drug Delivery & Development |

January 15, 2014

Replenishing Pipelines By Repurposing and Rescuing Pharmaceuticals

Life Science Leader Magazine |

May 1, 2013

Repurposing Drugs

Genetic Engineering & Biotechnology News |

January 30, 2013

News / Press Releases : Tonix In The News